[7]Sacituzumab govitecan (SG) versus treatment of physician’s choice (TPC) in patients (pts) with previously treated, metastatic triple-negative breast cancer (mTNBC): Final results from the phase 3 ASCENT study.ASCO 2022,...
前言 当地时间 12 月 6 日至 12 月 8 日,2024 年欧洲肿瘤内科学会亚洲年会(ESMO ASIA)于新加坡盛大召开,作为亚太地区讨论肿瘤学领域重磅突破的领先平台,ESMO ASIA 纳入了肺癌领域多方面最新研究进展,为患者构建了一座延续生命的桥梁...
2024;42(15):1738-1744. doi:10.1200/JCO.23.01409 [7]Sacituzumab govitecan (SG) versus treatment of physician’s choice (TPC) in patients (pts) with previously treated, metastatic triple-negative breast cancer (mTNBC): Final results from the phase 3 ASCENT study.ASCO 2022, Abstract 1071 [8...
2024年,ESMO转移性乳腺癌在线指南v.1.1版(ESMO Metastatic Breast Cancer Living Guideline V.1.1)将戈沙妥珠单抗(SG)治疗转移性三阴性乳腺癌(mTNBC)的ESMO临床获益量表(ESMO-MCBS)评分,由既往的4分调整为最高等级5分[1-2];目前,SG是mTNBC二线治疗唯一的首选推荐(I类证据,推荐等级A)。 这次推荐“升级”主要基...
Detailed instructions for the preparation of slide presentations and/or posters will be made available on the ESMO website by mid July 2024, in the section “Information for Presenters”. Abstract submission categories-摘要提交类别 *Abstracts may also be submitted to the Cancer nursing track. Submi...
提交指南>>>ESMO Sarcoma and Rare Cancers 2024 Abstract Regulations Submission categories Central Nervous System (CNS) Digestive cancers Genitourinary cancers Gynaecological cancers Head and neck cancers Neuroendocrine and Endocrine cancers Public Policy and Patient Advocacy ...
Detailed instructions for the preparation of slide presentations and/or posters will be made available on the ESMO website by mid July 2024, in the section “Information for Presenters”. Abstract submission categories-摘要提交类别 *Abstracts may also be submitted to the Cancer nursing track. Submi...
提交指南>>>ESMO Sarcoma and Rare Cancers 2024 Abstract Regulations Submission categories Central Nervous System (CNS) Digestive cancers Genitourinary cancers Gynaecological cancers Head and neck cancers Neuroendocrine and Endocrine cancers Public Policy and Patient Advocacy ...
Abstract Book of ESMO Breast Cancer 2024, Berlin, Germany, 15-17 May 2024Publication of this Abstract book is supported by the European Society for Medical Oncology May 2024 Previous vol/issue Next vol/issue Actions for selected articles
Abstract 8O. [2]Girard N, Okamoto I, Lisberg A, et al. Datopotamab deruxtecan (Dato-DXd) in patients with previously treated advanced non-small cell lung cancer (NSCLC): Nonsquamous (NSQ) histology in the phase III TROPION-Lung01 trial. ELCC 2024. 59P. [3]Ahn MJ, Tanaka K, ...